Stefan Maas

Stefan Maas has made significant contributions to understanding how aberrant A-to-I RNA editing by ADAR enzymes contributes to cancer progression, identifying specific edited transcripts that promote tumor growth, invasion, and drug resistance. His laboratory characterized the editing landscape across multiple cancer types and identified recurrent hyper-editing events at oncogene transcripts. He has contributed to understanding the interplay between RNA editing and the innate immune response in cancer. His work has established RNA editing as a therapeutically targetable process in oncology.